NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · Switzerland
Adc Therapeutics SA is a micro cap company (market value under $300 million) in the Drug Manufacturers - Specialty & Generic industry.
ADC Therapeutics is a commercial-stage company that develops antibody drug conjugates. ZYNLONTA, its CD19-directed therapeutic, is approved for treating relapsed or refractory diffuse large B-cell lymphoma after two or more prior systemic therapies. Headquartered in Switzerland with operations in New Jersey, the company specializes in ADC development and commercialization.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Adc Therapeutics SA stock.
Slightly overvalued: intrinsic value $1.45 per share, market price $1.53, margin of safety -5.3% (as of 2026-10-30).
A 0.6x revenue multiple, discounted for its losses, values the shares at $1.45; the price of $1.53 is 5% above that value.
13 more funds hold it; the full list is part of the paid plan.
All 84 Drug Manufacturers - Specialty & Generic stocks
11 more in this industry show a wider margin of safety.
ADCT is slightly overvalued (as of the 2026-10-30 close). A 0.6x revenue multiple, discounted for its losses, values the shares at $1.45; the price of $1.53 is 5% above that value.
$1.45 per share (as of the 2026-10-30 close), against a market price of $1.53. That is a margin of safety of -5.3%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.